Products
Mipletamig Biosimilar Bispecific scFv Antibody (CD123 × CD3) for Research
Cat No.: GMP-Bios-INN-1284
Anti-IL3RA/CD123 therapeutic antibody (Pre-made Mipletamig biosimilar,Bispecific Mixed scFv (scFv-CH2-CH3-scFv)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Mipletamig (development code APVO-436) is a bispecific antibody targeting IL-3 receptor alpha (IL3RA) and CD3. It is developed by Aptevo Therapeutics for acute myeloid leukemia and myelodysplastic syndromes. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1284-1mg | 1mg | |
| GMP-Bios-INN-1284-10mg | 10mg | |
| GMP-Bios-INN-1284-100mg | 100mg | |
| GMP-Bios-INN-1284-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Mipletamig biosimilar, Bispecific Mixed scFv (scFv-CH2-CH3-scFv), Anti-IL3RA/CD123;CD3E Antibody: Anti-CD123/IL3RA/Interleukin-3 receptor subunit alpha/IL-3 receptor subunit alpha therapeutic antibody |
| INN Name | Mipletamig |
| Target | IL3RA/CD123;CD3E |
| Format | Bispecific Mixed scFv (scFv-CH2-CH3-scFv) |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2024 |
| Year Recommended | 2024 |
| Companies | Aptevo Therapeutics |
| Conditions Approved | na |
| Conditions Active | Acute myeloid leukaemia;Myelodysplastic syndromes |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
